A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE) (Illuminate-X)

Trial Profile

A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE) (Illuminate-X)

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Oct 2016

At a glance

  • Drugs Tabalumab (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Adverse reactions; Registrational
  • Acronyms Illuminate-X
  • Sponsors Eli Lilly
  • Most Recent Events

    • 06 Jan 2016 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
    • 28 Oct 2015 Planned End Date changed from 1 Dec 2015 to 1 Nov 2015, as reported by ClinicalTrials.gov.
    • 28 Oct 2015 Planned primary completion date changed from 1 Jan 2015 to 1 Nov 2015, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top